Elimination of HCV in Russia: Barriers and Perspective

Isakov, Vasily; Nikityuk, D. B.

doi:10.3390/v14040790

Cited by 6 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, health systems should adopt strategies to increase testing with community-based hepatitis testing services and provide access to treatment for all grades of fibrosis. In some countries, including Russia, access to treatment is restricted to advanced fibrosis stages [ 26 ]. Lack of a healthcare policy regarding HCV treatment, deficient funding, and poor access to treatment are substantial barriers that must be conquered to reach the elimination of HCV.…”

Section: System-level Barriersmentioning

confidence: 99%

Hepatitis C Elimination: Opportunities and Challenges in 2023

Taha,

Ezra,

Abu-Freha

2023

Viruses

View full text Add to dashboard Cite

Hepatitis C Virus (HCV) infection is a leading etiology of liver cirrhosis and its associated complications, namely, decompensated cirrhosis. As such, hepatitis C potentially necessitates liver transplantation and may result in death. Recently, HCV treatment has evolved. Current HCV treatment is effective in curing HCV; some of the agents are pan-genotypic. Numerous countries have adopted an initiative to eliminate HCV. Achieving elimination poses many challenges; it requires improved availability and accessibility of pan-genotypic therapy. Barriers exist at the level of the collective healthcare system and at the level of the individual healthcare providers and patients. Therefore, organized national and local efforts are needed. Surmounting these barriers calls for interventions concerning screening, linkage to care, and treatment delivery. Pertinent barriers include inadequate availability of screening, ill-equipped laboratory testing before treatment, and insufficient access to treatment. Interventions should seek to decentralize laboratory testing and treatment provision, increase funding for resources and personnel, and spread awareness. Special consideration should be allocated to at-risk populations, such as intravenous drug users, refugees, and prisoners. Computerized medical filing and telemedicine have the potential to refine HCV management by enhancing detection, availability, accessibility, and cost-effectiveness.

show abstract

Section: System-level Barriersmentioning

confidence: 99%

Hepatitis C Elimination: Opportunities and Challenges in 2023

Taha,

Ezra,

Abu-Freha

2023

Viruses

View full text Add to dashboard Cite

show abstract

“…As shown by the results of a detailed analysis in Lithuania, as many as 41% of cirrhosis patients, 50% of liver cancer patients and 37% of patients requiring liver transplantation were infected with HCV [ 8 ]. However, in light of another work published as part of our Special Issue, the scale of problems related to HCV infections is much greater in Russia, where the most important barriers to HCV elimination are high prevalence of infection, low access to treatment, especially in populations at high risk of HCV infections, and centralization of the healthcare system, making linkage to care difficult [ 9 ].…”

Section: Testing and Linkage To Carementioning

confidence: 99%

Ways to Eliminate Viral Hepatitis as a Global Health Threat

Flisiak

Zarębska-Michaluk

Flisiak-Jackiewicz

2022

Viruses

View full text Add to dashboard Cite

show abstract

“…It has been shown that the incidence of hepatocellular carcinoma (HCC) increases 15–20 times in patients with CVHC [ 2 ]. Despite advances in treatment, the problem of CVHC remains very relevant due to the remaining significant pool of patients [ 3 , 4 ]. The most common CVHC genotypes in Russia are the first (56.6%) and the third (35.4%) [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Association of Blood NK Cell Phenotype with the Severity of Liver Fibrosis in Patients with Chronic Viral Hepatitis C with Genotype 1 or 3

Tsukanov,

Savchenko,

Cherepnin

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Background: NK cells phenotype and functional state in different genotypes of chronic viral hepatitis C (CVHC), depending on liver fibrosis severity, have not been sufficiently studied, which limits the possibilities for the development of pathology therapy. Methods: The CVHC diagnosis was based on the EASL recommendations (2018). Clinical examination with liver elastometry was performed in 297 patients with genotype 1 and in 231 patients with genotype 3 CVHC. The blood NK cells phenotype was determined by flow cytometry in 74 individuals with genotype 1 and in 69 individuals with genotype 3 CVHC. Results: The frequency of METAVIR liver fibrosis stages F3–F4 was 32.5% in individuals with genotype 3, and 20.5% in individuals with genotype 1 CVHC (p = 0.003). In patients with both genotype 1 and genotype 3 CVHC, a decrease in the total number of blood NK cells, CD56brightCD16+ NK cells and an increase in the proportion of CD56dimCD16+ NK cells, CD94+ and CD38 + CD73+ NK cells were registered in patients with fibrosis stage F3–F4 by METAVIR in comparison with persons with METAVIR fibrosis stage F0–F1. Conclusions: In patients with both genotype 1 and genotype 3 CVHC, an imbalance in the ratio between cytokine-producing and cytotoxic NK cells and an increase in the content of NK cells that express inhibitory molecules were determined in patients with severe liver fibrosis.

show abstract

Elimination of HCV in Russia: Barriers and Perspective

Cited by 6 publications

References 15 publications

Hepatitis C Elimination: Opportunities and Challenges in 2023

Hepatitis C Elimination: Opportunities and Challenges in 2023

Ways to Eliminate Viral Hepatitis as a Global Health Threat

Association of Blood NK Cell Phenotype with the Severity of Liver Fibrosis in Patients with Chronic Viral Hepatitis C with Genotype 1 or 3

Contact Info

Product

Resources

About